Inhibition of Interleukin-1-Induced Uveitis and Corneal Fibroblast Proliferation by Interleukin-1 Blockers

Chiou, George C.Y.; Xuan, Bo; Liu, Qin; Yamasaki, Tetsuo; Okawara, Tadashi

doi:10.1089/jop.2000.16.407

Cited by 10 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Inflammatory mediators involved in ocular disease have recently become of interest as potential therapeutic targets for the inhibition of inflammation in the eye, including nitric oxide synthase, tumor necrosis factor (TNF), interleukin-1 (IL-1), and cyclooxygenase-2 (COX-2)–generated prostanoids. 7,12 Prostanoids are the products of arachadonic acid (AA) metabolism by the COX enzymes. 5,6 Two isoforms of COX have been identified, COX-1 and COX-2.…”

mentioning

confidence: 99%

Cyclooxygenase-2 Expression in the Cornea of Dogs with Keratitis

2004

View full text Add to dashboard Cite

Cyclooxygenase-2 (COX-2) can be overexpressed at inflammatory sites, leading to the generation of proinflammatory prostanoids. Selective inhibitors of COX-2 have potential use in treating inflammatory conditions including ophthalmic diseases in veterinary medicine. Keratitis is considered the most common inflammatory eye disease in dogs. In this study we evaluated the expression of COX-2 in normal dog eyes and in dog eyes with keratitis by immunohistochemistry using isoform-specific antibodies. In the normal eye (n = 4), no COX-2 immunoreactivity was observed in the cornea. In keratitis, COX-2 (n = 12) expression was observed in all corneal layers (epithelium, stromal cells, and endothelium). COX-2 immunoreactivity was also noted in the stromal and epithelial cells of the iris and the stromal cells of the trabecular meshwork. These data indicate that COX-2 may play a pathophysiologic role in keratitis and suggest potential therapeutic implications of prostaglandin modulation in inflammatory eye diseases.

show abstract

mentioning

confidence: 99%

Cyclooxygenase-2 Expression in the Cornea of Dogs with Keratitis

2004

View full text Add to dashboard Cite

show abstract

“…Several studies have also shown that IL-1 is a potent stimulator of fibroblast proliferation (5,(7)(8)(9)26,27), and Inokuchi et al (28) demonstrated that IL-1α stimulates cell proliferation through Ca 2+ /calmodulindependent pathway in NIM 1 cells, a human thyroid cell line established from a patient with thyroid papillary adenocarcinoma. The findings of recent papers that the IL-1 blockers, CK-119 and CK-122 (29) and 1-methyl hydrazine analogs (30,31) inhibit the cell proliferation in human lung fibroblasts and fibroblast-like cells, respectively, also suggest that IL-1 enhances cell growth in fibroblasts.…”

Section: Discussionmentioning

confidence: 99%

The effect of IL-l.ALPHA. and nifedipine of cell proliferation and DNA synthesis in cultured human gingival fibroblasts

et al. 2005

View full text Add to dashboard Cite

The effect of nifedipine and interleukin-α (IL-1α) on the cell proliferation and DNA synthesis was studied in human gingival fibroblasts derived from 5 patients who developed gingival overgrowth (nifedipine responders) and 5 patients who did not develop gingival overgrowth (nifedipine non-responders) in response to nifedipine. Epidermal growth factor was used as a positive control. The fibroblasts derived from nifedipine responders tended to have a numerically greater rate of cell proliferation and DNA synthesis ( 3 H-thymidine incorporation) than those from nifedipine nonresponders in the presence of nifedipine and IL-1α. Fibroblasts derived from nifedipine responders showed significantly higher cell proliferation rate in the presence of nifedipine and IL-1α, than nifedipine or IL-1α alone on both the second and the fourth day of incubation (P < 0.05). A combination of IL-1α and epidermal growth factor also showed significantly greater cell proliferation than IL-1α alone on the second day (P < 0.05). The DNA synthesis rate with a combination of nifedipine and IL-1α was higher than that for nifedipine alone on the second day (P < 0.01), and IL-1α alone on the fourth day (P < 0.05) in gingival fibroblasts originating from nifedipine responders. These results suggest that the interaction between nifedipine and gingival inflammation might play an important role in the pathogenesis of nifedipine-induced gingival overgrowth. (J. Oral Sci. 47, [105][106][107][108][109][110] 2005)

show abstract

“…By inhibiting inflammatory cytokines like interleukin-1 (IL-1) and tumor necrosis factor-α, RLRL may lower their amounts [ 57 ]. Additionally, severe myopia may substantially raise IL-1 and IL-6 levels, which may be related to the myopic control mechanism [ 58 , 59 ]. According to a generally accepted theory, bright light causes the retina to produce and release more dopamine [ 60 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Repeated Low-Level Red Light (RLRL) therapy on myopia outcomes in children: a systematic review and meta-analysis

Youssef,

Shehata,

Adly

et al. 2024

BMC Ophthalmol

View full text Add to dashboard Cite

Background Myopia is the most prevalent form of refractive error that has a major negative impact on visual function and causes blurring of vision. We aimed to determine if Repeated Low-Level Red Light (RLRL) treatment is beneficial in treating childhood myopia in terms of axial length (AL), spherical equivalent refraction (SER), and sub foveal choroidal thickness (SFCT). Methods This systematic review was performed on RLRL for treatment of myopia in children compared to single vision spectacles (SVS). We employed the search strategy with key terms myopia and low-level light therapy then we searched PubMed, Scopus, Cochrane, and Web of Science databases. The mean differences (MD) were used to evaluate the treatment effects. Heterogeneity was quantified using I2 statistics and explored by sensitivity analysis. Results Five randomized controlled trials (RCTs) were included in our meta-analysis with a total of 833 patients, 407 in treatment group and 426 in control group. At a 3 month follow up period, pooled studies show a statistical difference in AL between RLRL and SVS group (MD = -0.16; 95% CI [-0.19, -0.12], SER (MD = 0.33; 95% CI [0.27, 0.38]), and SFCT (MD = 43.65; 95% CI [23.72, 45.58]). At a 6 month follow up period, pooled studies show a statistical difference in AL between RLRL and SVS group (MD = -0.21; 95% CI [-0.28, -0.15]), SER (MD = 0.46; 95% CI [0.26, 0.65]), and SFCT (MD = 25.07; 95% CI [18.18, 31.95]). At a 12 month follow up period, pooled studies show a statistical difference in AL between RLRL and SVS group (MD = -0.31; 95% CI [-0.42, -0.19]) and SER (MD = 0.63; 95% CI [0.52, 0.73]). Conclusion This is the first systematic review and meta-analysis investigating only RCTs evidence supporting the efficacy of 650 nm RLRL for myopia control in the short term of 3, 6, and 12 months follow up. The present review revealed the clinical significance of RLRL as a new alternative treatment for myopia control with good user acceptability and no documented functional or structural damage. However, the effect of long-term RLRL treatment and the rebound effect after cessation require further investigations.

show abstract

Inhibition of Interleukin-1-Induced Uveitis and Corneal Fibroblast Proliferation by Interleukin-1 Blockers

Cited by 10 publications

References 15 publications

Cyclooxygenase-2 Expression in the Cornea of Dogs with Keratitis

Cyclooxygenase-2 Expression in the Cornea of Dogs with Keratitis

The effect of IL-l.ALPHA. and nifedipine of cell proliferation and DNA synthesis in cultured human gingival fibroblasts

Efficacy of Repeated Low-Level Red Light (RLRL) therapy on myopia outcomes in children: a systematic review and meta-analysis

Contact Info

Product

Resources

About